Oligonucleotide-mediated AASS silencing as a potential therapeutic strategy for ALDH7A1 deficiency and glutaric aciduria type I
α-Aminoadipic semialdehyde synthase (AASS) catalyzes the first two steps of lysine catabolism. Inherited metabolic disorders affecting enzymes downstream of AASS, including α-aminoadipic semialdehyde dehydrogenase (ALDH7A1) deficiency, which causes pyridoxine-dependent epilepsy, and glutaric aciduria type I, cause accumulation of potentially neurotoxic lysine-derived metabolites. Current therapies incompletely prevent metabolite accumulation and neurological sequelae. We evaluated whether hepatic AASS silencing could reduce conversion of lysine into downstream metabolites. Antisense oligonucleotides and small interfering RNAs targeting AASS reduced disease-associated metabolites in patient-derived cells from individuals with ALDH7A1 deficiency and glutaric aciduria type I. Hepatocyte-selective delivery, enabled by N -acetylgalactosamine conjugation, achieved >90% liver-specific Aass knockdown in wild-type and Aldh7a1 knockout mice, with sustained protein suppression and reduced accumulation of downstream lysine-derived metabolites. These findings support further evaluation of oligonucleotide-mediated AASS silencing, including liver-directed delivery, as a substrate reduction strategy for ALDH7A1 deficiency and glutaric aciduria type I.
Authors
- Charalambos Demetriou (ORCID: https://orcid.org/0000-0001-6630-1322)
- Sam Rowley
- Julien Baruteau (ORCID: https://orcid.org/0000-0003-0582-540X)
- Joanna Toporowska (ORCID: https://orcid.org/0009-0009-4742-8497)
- Youssef Khalil (ORCID: https://orcid.org/0000-0001-9025-3017)
- Sreekanth Vootukuri Reddy (ORCID: https://orcid.org/0000-0002-5765-9362)
- Peter Theodore Clayton (ORCID: https://orcid.org/0000-0001-7592-4302)
- Nicholas D. E. Greene (ORCID: https://orcid.org/0000-0002-4170-5248)
- Izabella Agostinho Pena (ORCID: https://orcid.org/0000-0001-5242-3724)
- Katarzyna Dyjach (ORCID: https://orcid.org/0000-0001-7610-9035)
- Philippa B. Mills (ORCID: https://orcid.org/0000-0002-9704-1268)
- Sídney M. Gospe (ORCID: https://orcid.org/0000-0002-0099-109X)
- Haiyan Zhou (ORCID: https://orcid.org/0000-0001-8440-3074)
- Paul Gissen (ORCID: https://orcid.org/0000-0002-9712-6122)
- Kyle O’Sullivan
- Barbara Plecko
- Alex Mackensie
Institutions
- University of Ottawa (CA)
- Duke University (US)
- University of Washington (US)
- Medical University of Graz (AT)
- Children's Hospital of Eastern Ontario (CA)
- Great Ormond Street Hospital (GB)
- Great Ormond Street Hospital for Children NHS Foundation Trust (GB)
- Institute of Child Health (IN)
- Duke University Hospital (US)
- NIHR Great Ormond Street Hospital Biomedical Research Centre (GB)
- University College London (GB)
Publication Details
- Journal
- Science Translational Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1126/scitranslmed.aei9706
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- UK Research and Innovation
- National Institute for Health and Care Research
- Royal Society
- University College London
- National Natural Science Foundation of China
- Medical Research Council